ReviewFrontiers in immunology2026
Synergizing radiotherapy and immunotherapy for locally advanced gastric cancer: evolving paradigms and future directions.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article innovatively reviews and unveils the synergistic mechanisms, clinical research directions, and future challenges of the combination of preoperative radiotherapy (RT) and immunotherapy (especially the most popular belonging to immune checkpoint inhibitors, ICIs) in the treatment of locally advanced gastric cancer and gastroesophageal junction adenocarcinoma (GC/GEA). The integration of RT and ICIs represents a promising therapeutic strategy for locally advanced, even unresectable, GC/GEA. RT potentiates antitumor immunity by inducing immunogenic cell death (ICD) and targeting iron death, activating the cyclic Guanosine Monophosphate (GMP) and Adenosine Monophosphate (AMP) synthase-stimulator of interferon genes (STING protein) (cGAS-STING) signaling pathway, enhancing the expression level of the major histocompatibility complex (MHC) molecule and immune checkpoint proteins on tumor cells, and promoting immune cell infiltration into the tumor micro-environment. Trials with small sample sizes, such as Neo-PLANET and SHARED, have demonstrated that neoadjuvant chemoradiotherapy (NCRT) combined with ICIs yields encouraging pathological complete response (pCR, ranging from 22.6% to 38.2%) and high R0 resection rates with manageable toxicity profiles. Nevertheless, conflicting results from phase I-II trials like ECOG-ACRIN EA2174 underscore the necessity for patient stratification based on robust biomarkers. Current evidence regarding tumor cell programmed cell death protein ligand 1 (PD-L1) expression (namely, PD-L1 combined positive score or tumor proportion score), tumor mutational burden (TMB), and intratumoral immune micro-environment features for identifying responders still remains inconclusive. Future efforts should prioritize the validation of predictive biomarkers (containing the cutting-edge ctDNA), RT dose, and target area definition (especially for primary positive tumors and high-risk lymphatic drainage); optimization of RT-ICIs sequencing; and the conduct of large-scale randomized controlled trials to establish survival benefits and standardize combination protocols according to the stratified population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.